Sign into your account to have access to your paid resources

FORGOT YOUR PASSWORD?

FORGOT YOUR DETAILS?

AAH, WAIT, I REMEMBER NOW!

Clinical Education

  • LOGIN
  • MY ACCOUNT
  • Home
  • About
    • Our Philosophy
  • Upcoming Events
    • Private Practice Success 2021
    • Prescribing Lifestyle Medicine
    • Education Partnerships
    • BANT AGM and Conference 2021
  • Home Learning
    • CPD Seminars
    • nutrihub Advanced Course Part 1
  • Free Articles
    • News
    • Abstracts
    • Reviews
    • Newsletters
    • Audio
    • Video
    • Infographics
      • The Human Gut Microbiota
  • Contact
  • Home
  • Resources
  • Abstracts
  • Glutamine – Effective in resolution of Post Infective IBS

Glutamine – Effective in resolution of Post Infective IBS

by Michael Ash / Saturday, 15 September 2018 / Published in Abstracts
0
Reading Time: 2 minutes

gutjnl-2018-August-67-8-1373-F1.mediumFunctional gut problems such as IBS remain a considerable challenge to both clinician and patient. Finding safe and simple interventions as therapeutic strategies is an important part of ongoing research. Many practitioners are familiar with the use of the amino acid L-glutamine as a nutrient that confers benefit to gastro intestinal tracts experiencing increased levels of permeability and translocation of immune activating components such as LPS.

The journal Gut in August 2018 published a paper, the abstract of which is below confirming that for people with post infectious IBS glutamine provided considerable benefits and that further large-scale trials should be actioned.

BACKGROUND: More effective treatments are needed for patients with postinfectious, diarrhoea-predominant, irritable bowel syndrome (IBS-D). Accordingly, we conducted a randomised, double-blind, placebo-controlled, 8-week-long trial to assess the efficacy and safety of oral glutamine therapy in patients who developed IBS-D with increased intestinal permeability following an enteric infection.[1]

METHODS: Eligible adults were randomised to glutamine (5 g/t.i.d.) or placebo for 8 weeks. The primary end point was a reduction of =50 points on the Irritable Bowel Syndrome Severity Scoring System (IBS-SS). Secondary endpoints included: raw IBS-SS scores, changes in daily bowel movement frequency, stool form (Bristol Stool Scale) and intestinal permeability.

RESULTS: Fifty-four glutamine and 52 placebo subjects completed the 8-week study. The primary endpoint occurred in 43 (79.6%) in the glutamine group and 3 (5.8%) in the placebo group (a 14-fold difference). Glutamine also reduced all secondary endpoint means: IBS-SS score at 8 weeks (301 vs 181, p<0.0001), daily bowel movement frequency (5.4 vs 2.9±1.0, p<0.0001), Bristol Stool Scale (6.5 vs 3.9, p<0.0001) and intestinal permeability (0.11 vs 0.05; p<0.0001). ‘Intestinal hyperpermeability’ (elevated urinary lactulose/mannitol ratios) was normalised in the glutamine but not the control group. Adverse events and rates of study-drug discontinuation were low and similar in the two groups. No serious adverse events were observed.

CONCLUSIONS: In patients with IBS-D with intestinal hyperpermeability following an enteric infection, oral dietary glutamine supplements dramatically and safely reduced all major IBS-related endpoints. Large randomised clinical trials (RCTs) should now be done to validate these findings, assess quality of life benefits and explore pharmacological mechanisms.

Reference

[1] Zhou Q, Verne ML, Fields JZ, Lefante JJ, Basra S, Salameh H, Verne GN Randomised placebo-controlled trial of dietary glutamine supplements for postinfectious irritable bowel syndrome. Gut. 2018 Aug 14. View Abstract

Related posts:

  1. Glutamine Supplements Show Promise in Treating Stomach Ulcers
  2. Supplemental Dietary Glutamine Reduces H. Pylori-Related Pathology
  3. IBS Not Improved by St Johns Wort
  4. IBS And Food – Is There A Link?
Tagged under: GIT, glutamine, IBS, inflammation, LPS, permeability

Leave a Reply

Click here to cancel reply.

Recent Posts

  • Vaccine and Wild Type Immune Preparedness

    Vaccine and Wild Type Immune Preparedness

    Reading Time: 6 minutes Published 17th Februar...
  • COVID-19 Vs Sugar – Which is the bigger risk?

    COVID-19 Vs Sugar – Which is the bigger risk?

    Reading Time: 5 minutes As the UK progresses t...
  • Covid, Acute, Long, Women and Work

    Covid, Acute, Long, Women and Work

    Reading Time: 5 minutes As the roll out of vac...
  • Is a post COVID-19 Re-Set something we can progress?

    Is a post COVID-19 Re-Set something we can progress?

    Reading Time: 5 minutes It may be helpful to v...
  • Happiness – Denied by Distraction – A Solution

    Reading Time: 7 minutes Published 02 February ...

Keywords

A(H1N1) allergies antibiotics antioxidants autism autoimmune bacteria bias brain CAM cancer cardiovascular coeliac cytokines depression detoxification diet dysbiosis EFAs evidence fatty acids gluten gut gut health IBD IBS immune immunity inflammation microbiome microbiota mucosal nutrition obesity pregnancy prevention probiotics regulatory T cells research swine flu treatment virus Vitamin A vitamin D vitamins

Updates on your email

Don't miss out on our email updates

FACEBOOK

TWITTER

Tweets by @officalclined

CONTACT

Phone: 0333 241 4289
Fax: 08450 760 403

Clinical Education
Nutrition House
24 Milber Trading Estate
Newton Abbot
Devon
TQ12 4SG
United Kingdom

 
Clinical Education

Terms and Conditions

© 2021 Copyright Clinical Education. All rights reserved.

TOP
We use cookies and similar tools across our websites to improve their performance and enhance your user experience. I understand Learn more
Privacy & Cookies Policy
Necessary Always Enabled